Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HFT-290 in pediatric patients with cancer
jRCT2080223853Phase 3Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fentanyl in cancer pain and cancer, sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoint: Serum fentanyl concentration at steady state. Started Apr 2018; status: completed.
02
Drugs
fentanyl
03
Conditions
cancer paincancer
Beyond the preview
Go deeper on jRCT2080223853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223853.